Aged female mice given semaglutide late in life lived measurably longer than untreated animals, and the drug matched or exceeded the benefits of eating less on tests of memory, movement, and blood sugar control. Median lifespan rose from 742 days to 834 days, about 12 percent, according to the study published in Nature by a team at the University of California, Berkeley.
The result is already circulating online as evidence that Ozempic and Wegovy extend human life. It does not show that, not yet, and not in people. The animals were a single inbred strain of laboratory mouse, all female, treated beginning at 20 months of age. No human trial has tested whether semaglutide slows aging, and no regulator has approved a GLP-1 medicine for that purpose.
